New guidelines now recommend Type 2 diabetes patients can start with one of the newer diabetes medicine, one that can also reduce weight and protect the heart and kidney, Ariana Perez-Castells of The Wall Street Journal reports. These new guidelines could help people who are dealing with other conditions along with diabetes, such as hypertension, kidney disease, and obesity. However, the newer drugs cost more than metaformin, the typical drug received to treat type 2 diabetes, so not all patients will be able to afford these new drugs. The newer drugs include Ozempic, which is sold by Novo Nordisk (NVO), and Jardiance, which is sold by Eli Lilly (LLY). Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk named ‘Catalyst Driven Idea’ at Morgan Stanley
- Novo Nordisk reports 2022 EPS DKK 24.44 vs. DKK 20.74 last year
- Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
- Novo Nordisk announces FDA approval of label update for Rybelsus
- California AG files suit against drugmakers, PBMs over insulin prices